Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α Adrenoceptor Antagonists
Irreversible α antagonist (14-18 hours); inhibits reuptake of released norepinephrine; blocks histamine (H1), acetylcholine, and serotonin receptors; reduces BP when sympathetic tone is high (eg. standing up)
|
Orthostatic hypotension and tachycardia; nasal stuffiness and inhibition of ejaculation also occur; CNS symptoms – fatigue, sedation, nausea
|
Pheochromocytoma (tumor of the adrenal medulla or sympathetic ganglion cells that secretes catecholamines – symptoms include hypertension, headaches, palpitations, and increased sweating); occasionally Raynaud’s
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α Adrenoceptor Antagonists
Reversible; reduces peripheral resistance through blockade of α1 receptors and stimulates heart by antagonism of α2 receptors (↑ release of NE from sympathetic nerves)
|
Related to cardiac stimulation – severe tachycardia, arrhythmias, myocardial ischemia
|
Pheochromocytoma
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α1 Adrenoceptor Antagonists
Reversible; highly selective for α1 receptors; relaxes smooth muscle in vessels and prostate (half-life 3 hours)
|
Relative absence of tachycardia, orthostatic hypotension may be severe after first few doses, dizziness
first dose effect
|
Hypertension, occasionally Raynaud’s phenomenon and other conditions involving excessive reversible vasospasm, BPH
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α1 Adrenoceptor Antagonists
Reversible α1 antagonist (half-life 9-12 hours)
|
Orthostatic hypotension
first dose effect
|
Hypertension, benign prostatic hyperplasia (BPH)
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α1 Adrenoceptor Antagonists
Reversible α1 antagonist (half-life 9-12 hours)
|
Orthostatic hypotension
first dose effect
|
Hypertension, benign prostatic hyperplasia (BPH)
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α1 Adrenoceptor Antagonists
Reversible α1 antagonist, higher affinity for α1A and α1D than for the α1B subtype; greater potency in inhibiting contraction in prostate smooth muscle versus vascular
|
Less effect on standing BP
first dose effect
|
BPH
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α2 Adrenoceptor Antagonists
α2 selective antagonist; promotes NE release through blockade of presynaptic α2 receptors
|
Tachycardia, hypertension
|
Orthostatic hypotension, used for erectile dysfunction (replaced by phosphodiesterase-5 inhibitors)
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
β Adrenoceptor Antagonists
Block β1 and β2 receptors; lowers HR and BP, reduces renin; lipophilic crosses into CNS
|
Bradycardia, worsened asthma, fatigue, vivid dreams, cold hands
|
Hypertension, angina pectoris, arrhythmias, migraine, hyperthyroidism
|
|
|
|
Term
|
Definition
CH 10 Adrenoceptor-Antagonist Drugs
α and β Antagonist
Reversible α antagonist; has both α1 selective and β-antagonistic effects; lowers BP with less limited HR increase
|
Less tachycardia than other α1 agents
|
Hypertension; hypertensive emergencies
|
|
|
|